CN Patent

CN108366980A — 用于治疗恶性肿瘤的组合疗法

Assigned to Agios Pharmaceuticals Inc · Expires 2018-08-03 · 8y expired

What this patent protects

提供了用于使用突变体IDH2酶抑制剂以及AML诱导和巩固疗法的组合治疗携带IDH2突变的患者中的AML的方法和组合物。

USPTO Abstract

提供了用于使用突变体IDH2酶抑制剂以及AML诱导和巩固疗法的组合治疗携带IDH2突变的患者中的AML的方法和组合物。

Drugs covered by this patent

enasidenib-mesylate (ENASIDENIB MESYLATE)

Patent Metadata

Patent number: CN108366980A
Jurisdiction: CN
Classification: —
Expires: 2018-08-03
Drug substance claim: No
Drug product claim: No
Assignee: Agios Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.